What's happened
Eli Lilly has posted another quarter of strong results driven by Mounjaro and Zepbound, lifting full-year guidance. Novo Nordisk trails in growth momentum as it works to regain share and assure investors of a clear long-term path. Foundayo’s launch adds a new dimension to Lilly’s portfolio.
What's behind the headline?
Brief
- Lilly is extending its edge in the obesity-drug space, driven by sustained demand for Mounjaro and Zepbound.
- Novo Nordisk is expanding its footprint but faces headwinds from pricing pressure and the need for stronger pipeline signals.
- The market is watching Wegovy’s trajectory as it weighs against Lilly’s new oral drug Foundayo.
What’s Driving This
- Persistent demand for GLP-1 therapies is shaping a multi-year growth arc for leaders like Lilly.
- Price compression in the U.S. is a shared challenge, affecting revenue quality and investor sentiment.
- The pace of new product introductions and manufacturing capacity upgrades will determine long-term leadership in the space.
What Comes Next
- Investors will scrutinize 3Q results for signs of sustained volume growth and margin resilience.
- Anatomies of the competitive landscape will shift as new entrants and payer policies take hold.
How we got here
The obesity and diabetes drug sector has become a high-stakes battleground. Lilly’s performance underscores robust demand for tirzepatide therapies, while Novo Nordisk races to restore confidence in its pipeline amid price pressures and competitive launches. The market is watching how Wegovy and Mounjaro interplay with new oral options and broader payer dynamics.
Our analysis
- CNBC: Lilly beats estimates; raises full-year guidance as Mounjaro and Zepbound drive revenue growth. - Independent: Lilly’s half-year sales surge driven by Mounjaro and Zepbound with Foundayo contributing earlier traction. - CNBC: 2Q earnings show strong U.S. volume against price declines, with international growth offsetting U.S. price pressure.
Go deeper
- Will Lilly’s reformulated pipeline keep pressuring Novo Nordisk?
- How will Foundayo affect competition in the oral-weight loss market?
- What price trends will define the rest of 2026 for GLP-1 drugs?
More on these topics
-
Eli Lilly and Company - Pharmaceutical company
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a
-
People’s Republic of China - Country in East Asia
China, officially the People's Republic of China, is a country in East Asia. It is the world's most populous country, with a population of around 1.4 billion in 2019.
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.
-
United Kingdom - Country in Europe
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom or Britain, is a sovereign country located off the northwestern coast of the European mainland.
-
Novo Nordisk - Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company...